News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Bionomics Limited (BMICY.PK) Completes Enrollment for BNC105 Phase II Renal Cancer Trial


6/11/2013 9:25:10 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

ADELAIDE, South Australia, June 10, 2013 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX:BNO) has completed enrolment into a randomized Phase II clinical trial testing the combination of BNC105 plus everolimus (Afinitor) to treat patients with advanced renal cell carcinoma, the DisrupTOR-1 clinical trial.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES